JP2023552195A5 - - Google Patents
Info
- Publication number
- JP2023552195A5 JP2023552195A5 JP2023533878A JP2023533878A JP2023552195A5 JP 2023552195 A5 JP2023552195 A5 JP 2023552195A5 JP 2023533878 A JP2023533878 A JP 2023533878A JP 2023533878 A JP2023533878 A JP 2023533878A JP 2023552195 A5 JP2023552195 A5 JP 2023552195A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- lnp
- lipid
- immune cell
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121801P | 2020-12-04 | 2020-12-04 | |
| US63/121,801 | 2020-12-04 | ||
| US202163166205P | 2021-03-25 | 2021-03-25 | |
| US63/166,205 | 2021-03-25 | ||
| US202163169395P | 2021-04-01 | 2021-04-01 | |
| US202163169296P | 2021-04-01 | 2021-04-01 | |
| US63/169,395 | 2021-04-01 | ||
| US63/169,296 | 2021-04-01 | ||
| US202163172024P | 2021-04-07 | 2021-04-07 | |
| US63/172,024 | 2021-04-07 | ||
| PCT/US2021/072745 WO2022120388A2 (en) | 2020-12-04 | 2021-12-03 | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552195A JP2023552195A (ja) | 2023-12-14 |
| JP2023552195A5 true JP2023552195A5 (https=) | 2024-12-10 |
Family
ID=79287892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533878A Pending JP2023552195A (ja) | 2020-12-04 | 2021-12-03 | イオン化可能なカチオン性脂質および脂質ナノ粒子ならびにその合成および使用の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220218614A1 (https=) |
| EP (1) | EP4256067A2 (https=) |
| JP (1) | JP2023552195A (https=) |
| KR (1) | KR20230123480A (https=) |
| AU (1) | AU2021393593A1 (https=) |
| CA (1) | CA3201219A1 (https=) |
| CO (1) | CO2023007408A2 (https=) |
| IL (1) | IL303373A (https=) |
| MX (1) | MX2023006604A (https=) |
| PH (1) | PH12023500013A1 (https=) |
| TW (1) | TW202241458A (https=) |
| WO (1) | WO2022120388A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023184038A1 (en) | 2022-04-01 | 2023-10-05 | Nanovation Therapeutics Inc. | Mrna delivery method and composition thereof |
| AU2023290487A1 (en) * | 2022-06-14 | 2025-01-30 | Ablynx Nv | Immunoglobulin single variable domains targeting t cell receptor |
| WO2024079046A1 (en) * | 2022-10-10 | 2024-04-18 | Zelarion Malta Limited | Anti-cd2 antibodies for type 1 diabetes |
| EP4630061A1 (en) * | 2022-12-08 | 2025-10-15 | Nanovation Therapeutics Inc. | Lipid nanoparticles comprising elevated neutral lipid and a targeting moiety for targeted delivery of nucleic acid |
| WO2024200820A1 (en) * | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| EP4687991A1 (en) * | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024216171A2 (en) * | 2023-04-13 | 2024-10-17 | Massachusetts Institute Of Technology | Lipid nanoparticles for delivery of agents |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025029975A1 (en) * | 2023-07-31 | 2025-02-06 | Jibe Therapeutics, Inc. | Compositions for redirecting immunoglobulins to immune cells |
| WO2025059607A1 (en) * | 2023-09-13 | 2025-03-20 | Tessera Therapeutics, Inc. | Lipid nanoparticles for delivery of therapeutic payloads to cells |
| AU2024358609A1 (en) * | 2023-10-13 | 2026-04-09 | Nanocell Therapeutics Holdings B.V. | Means and methods for delivery of agents to immune effector cells |
| TW202547451A (zh) * | 2023-12-13 | 2025-12-16 | 美商泰德治療公司 | 可電離陽離子脂質和脂質奈米顆粒及其合成方法和用途 |
| US20250332281A2 (en) * | 2023-12-15 | 2025-10-30 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| WO2025143892A1 (ko) * | 2023-12-29 | 2025-07-03 | 주식회사 삼양홀딩스 | 약물전달용 나노입자의 조성물 |
| WO2025169168A1 (en) * | 2024-02-09 | 2025-08-14 | Nanocell Therapeutics Holdings B.V. | Extracorporeal transfection of immune effector cells |
| WO2025184694A1 (en) * | 2024-03-04 | 2025-09-12 | The University Of Melbourne | Nanoparticles and uses thereof |
| TW202543585A (zh) | 2024-03-08 | 2025-11-16 | 美商健臻公司 | 脂質奈米粒子 |
| WO2025213153A2 (en) * | 2024-04-05 | 2025-10-09 | Transcera Inc. | Compounds for lysosomal degradation of target proteins |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
| WO2026083328A1 (en) | 2024-10-18 | 2026-04-23 | Precision Biosciences, Inc. | Base editing nucleotide sequences using homology directed repair |
| WO2026083329A1 (en) | 2024-10-18 | 2026-04-23 | Precision Biosciences, Inc. | Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| DE69325738T2 (de) | 1992-04-28 | 2000-01-27 | Sumitomo Rubber Industry Ltd., Kobe | Fester Golfball |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US6849258B1 (en) | 1997-07-18 | 2005-02-01 | Universite Catholique De Louvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| SG144925A1 (en) | 2003-08-04 | 2008-08-28 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| EP1656128A4 (en) | 2003-08-12 | 2007-02-28 | William M Yarbrough | SINGLE ACNE TREATMENT AND METHOD OF USE |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| WO2009100140A1 (en) | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| NZ595461A (en) | 2009-04-10 | 2013-01-25 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| WO2011000107A1 (en) * | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| US8569256B2 (en) * | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| EP3494963A1 (en) | 2009-12-18 | 2019-06-12 | The University of British Columbia | Methods and compositions for delivery of nucleic acids |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| JP6620093B2 (ja) * | 2013-07-23 | 2019-12-11 | アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ | メッセンジャーｒｎａを送達するための組成物及び方法 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| EP4707303A2 (en) | 2014-05-16 | 2026-03-11 | Ablynx NV | Improved immunoglobulin variable domains |
| EP3247398A4 (en) | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| AU2016253972B2 (en) * | 2015-04-27 | 2020-01-02 | Acuitas Therapeutics Inc. | Nucleoside-modified RNA for inducing an adaptive immune response |
| EP4667492A3 (en) * | 2015-05-26 | 2026-04-15 | Ramot at Tel-Aviv University Ltd. | Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes |
| PT3313829T (pt) | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
| US20180271998A1 (en) * | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
| TWI894123B (zh) * | 2017-12-27 | 2025-08-21 | 日商武田藥品工業有限公司 | 含核酸之脂質奈米粒子及其用途 |
| KR20210039983A (ko) * | 2018-04-24 | 2021-04-12 | 리간달 인코포레이티드 | 게놈 편집을 위한 방법 및 조성물 |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| WO2020023559A1 (en) | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy |
-
2021
- 2021-12-02 PH PH1/2023/500013A patent/PH12023500013A1/en unknown
- 2021-12-03 IL IL303373A patent/IL303373A/en unknown
- 2021-12-03 KR KR1020237022607A patent/KR20230123480A/ko active Pending
- 2021-12-03 AU AU2021393593A patent/AU2021393593A1/en active Pending
- 2021-12-03 WO PCT/US2021/072745 patent/WO2022120388A2/en not_active Ceased
- 2021-12-03 CA CA3201219A patent/CA3201219A1/en active Pending
- 2021-12-03 EP EP21840391.3A patent/EP4256067A2/en active Pending
- 2021-12-03 US US17/542,348 patent/US20220218614A1/en active Pending
- 2021-12-03 JP JP2023533878A patent/JP2023552195A/ja active Pending
- 2021-12-03 MX MX2023006604A patent/MX2023006604A/es unknown
- 2021-12-06 TW TW110145547A patent/TW202241458A/zh unknown
-
2023
- 2023-06-05 CO CONC2023/0007408A patent/CO2023007408A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023552195A5 (https=) | ||
| US20260102510A1 (en) | Conditioning for in vivo immune cell engineering | |
| US12239736B2 (en) | Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof | |
| JP2025505603A (ja) | 細胞への標的化送達のための薬剤および方法 | |
| TW202327647A (zh) | 用以治療cldn6陽性癌症之藥劑 | |
| WO2022067091A1 (en) | Systems and methods for expressing biomolecules in a subject | |
| US20250281405A1 (en) | Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof | |
| KR20250007062A (ko) | Epo 수용체 효능제 및 길항제 | |
| WO2020053325A1 (en) | Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof | |
| WO2025087303A1 (en) | Lipid nanoparticle with non-covalent bifunctional binders for active targeting | |
| JP2012506371A (ja) | 樹状細胞を標的とするための組成物 | |
| US20250235532A1 (en) | Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof | |
| JP2024522607A (ja) | 治療薬の標的化送達のための組成物及び方法 | |
| RU2024139944A (ru) | Ионизируемые катионные липиды и липидные наночастицы, а также способы их синтеза и применения | |
| JP2024522316A5 (https=) | ||
| US20250381150A1 (en) | Lipid nanoparticles | |
| CN120359047A (zh) | 用于靶向递送治疗剂的组合物和方法 | |
| WO2025106529A2 (en) | Compositions for targeting muscle cells and uses thereof | |
| WO2024092352A1 (en) | Compositions that recruit and activate antigen presenting cells | |
| CN118973618A (zh) | 用于将核酸靶向递送至细胞的药剂和方法 | |
| HK40113807A (zh) | 用於将核酸靶向递送至细胞的药剂和方法 | |
| HK40114081A (zh) | 用於靶向递送至细胞的药剂和方法 | |
| CN118973619A (zh) | 用于靶向递送至细胞的药剂和方法 | |
| WO2026085300A1 (en) | Compositions and methods | |
| WO2026034573A1 (ja) | Ｃｄ３２０に結合する抗体およびその断片、並びに前記抗体を含む抗体薬物コンジュゲート |